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OBJECTIVES The purpose of the study was to examine the safety and efficacy of 17-beta-estradiol–eluting
stent implantation on coronary de novo lesions.
BACKGROUND Recent animal data indicate that local delivery of 17-beta-estradiol promotes re-
endothelialization, inhibits cell migration and proliferation, and prevents restenosis.
METHODS A total of 30 consecutive patients underwent 17-beta-estradiol–eluting BiodVysio (Biocom-
patibles Ltd., London, United Kingdom) stent implantation for the treatment of coronary
de novo lesions. Clinical, angiographic, and intravascular ultrasound (IVUS) analysis was
performed at six-month follow-up.
RESULTS All stents were successfully deployed and patients were discharged home without clinical
events. A total of two patients exceeded 50% intra-stent narrowing by angiography, whereas
no patients experienced edge restenosis. One patient had focal intra-stent restenosis (60%
diameter stenosis) with no symptoms and negative stress test, whereas the other patient had
diffuse restenosis, requiring target vessel revascularization. No other patient experienced any
major adverse cardiac event. Follow-up IVUS revealed a neointimal hyperplasia volume of
32.3 16.4 mm3, whereas the stent volume was 143.7 43.7 mm3, resulting in a neointimal
volume obstruction of 23.5  12.5%. None of the patients had 50% volume obstruction by
IVUS.
CONCLUSIONS Implantation of 17-beta-estradiol–eluted BiodVysio stents appears feasible and safe, showing
low rates of binary restenosis and revascularization. These results warrant further confirma-
tion with a large, randomized multicenter trial. (J Am Coll Cardiol 2004;43:1118–21)
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voronary stent implantation has been proven superior to
onventional balloon angioplasty for the treatment of cor-
nary de novo lesions (1–4). However, coronary stenting
rocedures are still burdened with an unacceptable high
estenosis rate. Utilization of antiproliferative agents deliv-
red locally via drug-eluting stents has dramatically reduced
hese rates (5–7) . However, as in the case of brachytherapy,
oncern remains regarding delayed healing of the arterial
all and the long-term effects of cell-cycle inhibitors. An
lternative approach for the prevention of in-stent restenosis
nvolves the use of a naturally occurring vasculoprotective
ormone such as 17-beta-estradiol, which has a low molec-
lar weight and is hydrophobic and lipophilic, making it
harmacokinetically suitable for loading on a stent delivery
ystem. Recent animal data suggest that the local delivery of
7-beta-estradiol either via an infusion catheter or impreg-
From the *Institute Dante Pazzanese of Cardiology, Sa˜o Paulo, Brazil; †University
f Florida-Shands, Jacksonville, Florida; ‡Lenox Hill Hospital, New York, New
ork; §Cardiovascular Research Foundation, New York, New York; and Box Hill
ospital, Melbourne, Australia.
Manuscript received August 5, 2003; revised manuscript received December 4,t003, accepted December 9, 2003.ated on a stent inhibits neointimal proliferation without
ffecting endothelial repair and function (8–10). To date,
he safety and efficacy of the 17-beta-estradiol–eluting stent
ystem on neointimal proliferation in human coronaries has
ot been reported. The purpose of the Estrogen And Stents
o Eliminate Restenosis (EASTER) study was to evaluate
he feasibility of 17-beta-estradiol–eluting stents to inhibit
estenosis in humans.
ETHODS
his was a single-center prospective trial of 30 patients who
ere scheduled to undergo elective percutaneous interven-
ion for single, short (18 mm in length), de novo lesions
n native coronary arteries having a diameter between 2.5
nd 3.5 mm. All patients received aspirin (325 mg/day,
ndefinitely) at least 12 h before the procedure, and clopi-
ogrel (300 mg at least 6 h prior to stent implantation and
5 mg daily continued for 60 days). All patients under-
ent angiographic and intravascular ultrasound (IVUS)
ollow-up at six months. The patients returned for clinical
isits at 30 days, 6 months, and 12 months, during which
ime the physicians were blinded to the angiographic and
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edical Ethics Committee of the Institute Dante Pazza-
ese of Cardiology, and informed consent was obtained
rom every patient.
oading 17-beta-estradiol stents. The BiodivYsio stent
elivery system (Biocompatibles Ltd., London, United
ingdom) is a laser cut, 316L stainless steel balloon-
xpandable stent coated with phosphorylcholine (PC), a
aturally occurring biological substance. The biocompatible
C coating constitutes a 50- to 100-m thick double layer
f synthetic PC headgroup coating that is able to adsorb a
rug via a “sponge-like” mechanism. Safety of this PC
eadgroup coating has been previously reported (11). The
ethod of impregnating the PC coating involves three
teps. First, immersing the stent into a solution of 17-beta-
stradiol (in ethanol) for 5 min. After removal of the stent
rom the solution and allowing it to dry for 1 min, a second
tep whereby 10 l of the same solution is pipetted onto the
tent. The PC polymer absorbs the solution like a sponge.
he stent is again allowed to air-dry for 1 min. This process
s repeated, but with 5 min of air-drying (total preparation
ime, 12 min). The stent is then immediately deployed.
aboratory testing has demonstrated that a consistent
mount of drug (2.52 g/mm2) can be impregnated using
his method.
rocedure. Each patient received one 18-mm stent (3.0 to
.5 mm in diameter). All lesions were pre-dilated. Stents
ere deployed at high pressure (14 atm) and the need for
ost-dilation was guided by IVUS.
uantitative measurements. Baseline, post-procedure,
nd six-month follow-up quantitative coronary angiog-
aphy (QCA) analysis was performed in all patients by an
ndependent core laboratory (Cardiovascular Imaging
ore Laboratories, University of Florida, Jacksonville,
lorida). Quantitative measurements of the in-stent and
n-lesion segments (in-stent segment plus 5-mm edge
roximally and distally) were performed in two orthogo-
al projections. The IVUS imaging was performed in all
atients post-procedure and at follow-up. The IVUS
mages were acquired using motorized pullback at a
onstant speed of 0.5 mm/s (Galaxy, Boston Scientific,
atick, Massachusetts). Three-dimensional IVUS volu-
etric analysis was performed by an independent core
aboratory (Cardiovascular Imaging Core Laboratories,
niversity of Florida). Percent volume obstruction was
efined as the ratio of the volume of neointimal hyper-
lasia to the volume of the stent multiplied by 100.
tatistical analysis. Statistical analysis was performed with
Abbreviations and Acronyms
IVUS  intravascular ultrasound
PC  phosphorylcholine
QCA  quantitative coronary angiographyhe aid of the commercially available software (SPSS Ver- vion 11, SPSS Inc., Chicago, Illinois). Quantitative data are
resented as rates or mean value  SD. Probability values
re two-sided from the Student t test for continuous
ariables and the Fisher exact test for categorical variables. A
alue of p  0.05 was considered significant.
ESULTS
he mean age of the patients was 61  12 years. A total of
1 patients (70%) were men. Systemic hypertension was the
ost frequent coronary risk factor, involving 15 patients
50%), followed by smoking in 10 patients (33%), and
yslipidemia in 8 patients (27%), whereas only 3 patients
10%) were diabetics. Eleven patients (37%) had a prior
istory of myocardial infarction. The procedure was suc-
essful in all patients. There were no in-hospital events,
ncluding no elevation of cardiac enzymes post-procedure.
ne patient underwent target lesion revascularization at
ix-month follow-up due to symptomatic angiographic re-
tenosis. All other patients were asymptomatic at six-month
ngiographic follow-up. No stent thrombosis occurred,
here were no other major cardiovascular events (including
eath, myocardial infarction, stroke, or target vessel revas-
ularization) up to 12-month clinical follow-up.
ngiographic follow-up. Angiographic results are pre-
ented in Table 1 and Figure 1. Mean lesion length was
.1  2.4 mm. Two patients developed in-stent restenosis
50% diameter stenosis). One patient with a 60% lesion
as asymptomatic with negative noninvasive stress test and
id not undergo repeat revascularization. No restenosis
ccurred at the stent-edge segments, and in-segment late
oss was only 0.34 mm.
ix-month IVUS analysis. The neointimal hyperplasia
olume amounted to 32.3  16.4 mm3 with a stent
3
able 1. Offline Quantitative Coronary Analysis by Core
aboratory
Parameters N  30
efore procedure
RD, mm 2.80  0.56
MLD, mm 1.12  0.41
DS, % 60.45  10.40
Lesion length, mm 8.96  3.33
fter procedure
RD, mm 2.76  0.56
In-segment MLD, mm 2.04  0.43
In-stent MLD, mm 2.44  0.52
In-segment DS, % 23.4  10.9
In-stent DS, % 13.6  10.4
ollow-up
RD, mm 2.54  0.60
In-segment MLD, mm 1.76  0.56
In-stent MLD, mm 1.89  0.57
In-segment DS, % 30.5  14.9
In-stent DS, % 28.2  14.8
In-segment late loss, mm 0.31  0.38
In-stent late loss, mm 0.54  0.44
S  diameter stenosis; MLD  minimal lumen diameter; RD  reference
iameter.olume of 143.7  43.7 mm , resulting in a mean
n
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atient had 50% volume obstruction by IVUS. No
vidence was seen of stent malapposition or echolucent
mages (“black-hole”).
ISCUSSION
his study is the first human experience with 17-beta-
stradiol– eluting stents for the prevention of restenosis.
linical outcomes up to one-year follow-up suggest that
he use of 17-beta-estradiol– eluted PC-coated stents is
afe and feasible, with a low incidence of restenosis and
ithout associated local or systemic toxicity. Only one
atient (out of 30 patients) required target vessel revas-
ularization. The angiographic and IVUS follow-up re-
ults at six months demonstrated a low amount of intimal
yperplasia and late loss, which compares favorably with
revious studies testing the same PC-coated BiodivYsio
Biocompatibles Ltd.) stents without estradiol (Fig. 2).
n addition, there was minimal in-segment late loss and
o edge restenosis. Nevertheless, neointimal proliferation
as not completely abolished by estradiol-eluting stents.
t is possible that drug dosing, absorption, and elution
inetics may have influenced our results and partially
imited the anti-proliferative effects of estradiol. Estra-
iol eluting from “hand”-loaded PC-coated stents is only
arried out within the first 24-h interval (Fig. 3). None-
heless, the amount of intimal hyperplasia detected by
VUS in the present study compares favorably with bare
etal stents (12) suggesting an anti-restenotic effect of
stradiol despite the suboptimal stent elution.
igure 1. Cumulative distribution curves of in-stent (A) and in-lesion (B
ngiographic follow-up.Estradiol is the most potent naturally occurring female sormone. It is well known that premenopausal women have
low incidence of coronary heart disease (13). Many
xperimental studies have demonstrated that estradiol has a
asculoprotective effect mediated via a number of cellular
echanisms (14). In particular, estradiol can inhibit smooth
uscle cell proliferation and migration (15), accelerate
e-endothelialization (16), and restore normal endothelial
unction following balloon artery injury (8,17). Inhibition of
eointimal proliferation and accelerated re-endothelialization
nd function with the injection of 17-beta-estradiol follow-
ng balloon angioplasty in a pig model has been recently
eported (8). In addition, pre-clinical work with the same
tent, dose, and loading process of 17-beta-estradiol as in
his study, suggests a 40% reduction in in-stent neo-intimal
ormation (11). Estradiol is known to have pleomorphic
roperties. It has anti-atherogenic, anti-inflammatory, and
igure 2. Late-loss comparison between phosphorylcholine (PC)-coated
centage diameter stenosis (%DS) and in-stent late loss (C) at six-month) pertent trials with and without estradiol.
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hese features may contribute to its vasculoprotective effect
nd may also make it a potential agent in the treatment of
ulnerable plaque.
No stent thrombosis occurred despite the short dura-
ion of antiplatelet therapy in the present study. In
ddition, late-stent malapposition was not detected by
VUS, late-loss at the stent margins (in-segment analy-
is) was minimal, and no edge restenosis was found at
ix-month follow-up. Hence, an adequate safety profile
f the 17-beta-estradiol– eluted stent was demonstrated
n the present study.
tudy limitations. As most pilot studies, this “First-in-
an” experience included only 30 patients with de novo,
ingle-vessel coronary lesions. However, the present data
rovide important information about the safety and poten-
ial of this technology to prevent restenosis. Whether
imilar results are reproducible in a larger population with
ore complex lesion morphology in a randomized trial
emains to be tested.
The loading of 17-beta-estradiol onto the stent was
erformed in the catheterization laboratory just prior to
tent insertion. Although a strict recipe for loading was
dhered to, because this process was a “manual” method,
ack of good reproducibility by this technique could result in
arying doses of the hormone being loaded onto the stent.
his “manual” loading process is also not practical, and
re-loaded stents would eliminate this problem. Theoreti-
ally, pre-loaded stents with different pharmacokinetics,
igher drug doses, and more homogeneous and pro-
rammed drug release may further improve the results
bserved in the present study. A second phase of EASTER
ith pre-loaded 17-beta-estradiol–eluting stents is ongoing
n Europe.
onclusions. This is the first study in humans to demon-
trate that 17-beta-estradiol–eluting stents are feasible and
afe. Low rates of restenosis and revascularization were
bserved. At 1-year follow-up, these results appear to be
ustained. These seminal observations suggest that vasculo-
rotective agents such as estradiol may provide an alterna-
ive approach to anti-proliferative agents in the prevention
f restenosis and warrant further investigation with a large,
andomized multicenter trial.
igure 3. Graph showing the phosphorylcholine polymer local delivery
harmacokinetics of 17-beta-estradiol. Total drug delivery is completed
ithin the first 24 h.eprint requests and correspondence: Dr. Alexandre Abizaid,
v. Dr. Dante Pazzanese 500, Ibirapuera, Sa˜o Paulo, SP, Brazil,
EP: 04012-909. E-mail: aabizaid@uol.com.br.
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